Acceleron Pharma Inc. (XLRN) Director Jean George Sells 453,505 Shares of Stock
Acceleron Pharma Inc. (NASDAQ:XLRN) Director Jean George sold 453,505 shares of Acceleron Pharma stock in a transaction that occurred on Thursday, November 17th. The shares were sold at an average price of $38.39, for a total transaction of $17,410,056.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Jean George also recently made the following trade(s):
- On Friday, September 30th, Jean George sold 857,145 shares of Acceleron Pharma stock. The shares were sold at an average price of $35.50, for a total transaction of $30,428,647.50.
Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) traded down 3.29% during mid-day trading on Monday, hitting $36.71. 74,446 shares of the stock traded hands. The stock’s market cap is $1.39 billion. Acceleron Pharma Inc. has a one year low of $22.67 and a one year high of $50.86. The stock has a 50-day moving average of $32.08 and a 200 day moving average of $32.93.
Acceleron Pharma (NASDAQ:XLRN) last announced its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by $0.02. The company had revenue of $3 million for the quarter, compared to analysts’ expectations of $4.08 million. Acceleron Pharma had a negative return on equity of 30.75% and a negative net margin of 229.77%. Equities analysts predict that Acceleron Pharma Inc. will post ($1.58) EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Fund Advisors raised its position in Acceleron Pharma by 16.2% in the first quarter. BlackRock Fund Advisors now owns 1,070,110 shares of the biopharmaceutical company’s stock valued at $28,240,000 after buying an additional 149,193 shares during the last quarter. Nationwide Fund Advisors raised its position in Acceleron Pharma by 8.7% in the second quarter. Nationwide Fund Advisors now owns 25,951 shares of the biopharmaceutical company’s stock valued at $882,000 after buying an additional 2,077 shares during the last quarter. Acrospire Investment Management LLC acquired a new position in Acceleron Pharma during the second quarter valued at approximately $110,000. Alps Advisors Inc. raised its position in Acceleron Pharma by 25.3% in the second quarter. Alps Advisors Inc. now owns 52,287 shares of the biopharmaceutical company’s stock valued at $1,777,000 after buying an additional 10,569 shares during the last quarter. Finally, Strs Ohio acquired a new position in Acceleron Pharma during the second quarter valued at approximately $570,000. Hedge funds and other institutional investors own 79.32% of the company’s stock.
A number of research analysts recently weighed in on the stock. Leerink Swann restated an “outperform” rating on shares of Acceleron Pharma in a report on Friday, October 7th. Zacks Investment Research upgraded shares of Acceleron Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, October 12th. Citigroup Inc. assumed coverage on shares of Acceleron Pharma in a report on Thursday, September 29th. They issued a “neutral” rating and a $40.00 price objective for the company. FBR & Co restated a “buy” rating on shares of Acceleron Pharma in a report on Wednesday, September 28th. Finally, Credit Suisse Group AG reiterated a “buy” rating and set a $42.00 price target on shares of Acceleron Pharma in a report on Wednesday, September 28th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Acceleron Pharma currently has a consensus rating of “Buy” and an average price target of $47.11.
About Acceleron Pharma
Acceleron Pharma Inc is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia.
Receive News & Stock Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related stocks with our FREE daily email newsletter.